NTRK1 and neoplasm: Battle et al. [21] showed the inhibitory effect of sunitinib, a Food and Drug Administration (FDA) approved multi-targeted receptor tyrosine kinase (RTK) inhibitor, on the uptake of 18F-fluciclatide (formerly known as 18F-AH111585) by αVβ3-positive U87MG tumors as revealed by repeated PET imaging during the 2-weeks treatment period; they also found a reduction in the tumor MVD at the end of the therapy.